PL2977056T3 - Transferryna do zastosowania w leczeniu zaburzeń neurodegeneracyjnych związanych z czynnikiem indukowanym hipoksją (HIF) - Google Patents

Transferryna do zastosowania w leczeniu zaburzeń neurodegeneracyjnych związanych z czynnikiem indukowanym hipoksją (HIF)

Info

Publication number
PL2977056T3
PL2977056T3 PL15171056T PL15171056T PL2977056T3 PL 2977056 T3 PL2977056 T3 PL 2977056T3 PL 15171056 T PL15171056 T PL 15171056T PL 15171056 T PL15171056 T PL 15171056T PL 2977056 T3 PL2977056 T3 PL 2977056T3
Authority
PL
Poland
Prior art keywords
hif
transferrin
treatment
neurodegenerative disorders
inducible factor
Prior art date
Application number
PL15171056T
Other languages
English (en)
Inventor
David A. Ross
Ralph Christian Crumrine
Original Assignee
Grifols Worldwide Operations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Limited filed Critical Grifols Worldwide Operations Limited
Publication of PL2977056T3 publication Critical patent/PL2977056T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
PL15171056T 2014-07-11 2015-06-08 Transferryna do zastosowania w leczeniu zaburzeń neurodegeneracyjnych związanych z czynnikiem indukowanym hipoksją (HIF) PL2977056T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462023446P 2014-07-11 2014-07-11
EP15171056.3A EP2977056B1 (en) 2014-07-11 2015-06-08 Transferrin for use in the treatment of hypoxia inducible factor (hif)-related neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PL2977056T3 true PL2977056T3 (pl) 2019-03-29

Family

ID=53385523

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15171056T PL2977056T3 (pl) 2014-07-11 2015-06-08 Transferryna do zastosowania w leczeniu zaburzeń neurodegeneracyjnych związanych z czynnikiem indukowanym hipoksją (HIF)
PL17200065T PL3300742T3 (pl) 2014-07-11 2015-06-08 Transferryna do stosowania w leczeniu zaburzeń związanych z czynnikiem indukowanym hipoksją (HIF) takich jak niedokrwienie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17200065T PL3300742T3 (pl) 2014-07-11 2015-06-08 Transferryna do stosowania w leczeniu zaburzeń związanych z czynnikiem indukowanym hipoksją (HIF) takich jak niedokrwienie

Country Status (26)

Country Link
US (2) US9687530B2 (pl)
EP (3) EP3795171B1 (pl)
JP (1) JP6517100B2 (pl)
KR (3) KR102219557B1 (pl)
CN (1) CN105288598A (pl)
AR (1) AR101133A1 (pl)
AU (3) AU2015203264B2 (pl)
BR (1) BR102015015916A2 (pl)
CA (3) CA2894239C (pl)
CL (1) CL2015001936A1 (pl)
ES (2) ES2843783T3 (pl)
FI (1) FI3795171T3 (pl)
HK (1) HK1220895A1 (pl)
HU (1) HUE053104T2 (pl)
IL (1) IL239655B (pl)
MX (1) MX359029B (pl)
MY (1) MY184341A (pl)
NZ (1) NZ709399A (pl)
PL (2) PL2977056T3 (pl)
PT (3) PT2977056T (pl)
RU (1) RU2686308C2 (pl)
SG (2) SG10201811078XA (pl)
TR (1) TR201815058T4 (pl)
TW (1) TWI704926B (pl)
UY (1) UY36173A (pl)
ZA (2) ZA201504705B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107831315B (zh) * 2017-10-31 2019-11-05 中国科学院昆明动物研究所 转铁蛋白标志物及其应用
IL299183A (en) * 2020-07-08 2023-02-01 Grifols Worldwide Operations Ltd Preparations with neuroregenerative applications
KR20230038194A (ko) * 2020-07-08 2023-03-17 그리폴즈 월드와이드 오퍼레이션스 리미티드 신경재생 응용성을 가진 조성물
RU2747653C1 (ru) * 2021-01-11 2021-05-11 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ диагностики нарушения обмена железа при тяжелых формах covid-19
EP4052723A1 (en) 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen
EP4311556A1 (en) 2022-07-28 2024-01-31 Grifols Worldwide Operations Limited Antithrombin in stroke

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5986067A (en) * 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
EP1143253A1 (en) * 1992-07-10 2001-10-10 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
IT1278136B1 (it) * 1995-07-12 1997-11-17 Piera Valenti Associazione costituita dsa lattoferrina (o suoi analoghi) e deferossamina metalsulfonato (o altri chelanti ioni metallici) per
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6004986A (en) * 1997-05-08 1999-12-21 The University Of Virginia Patent Foundation Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceutical compositions therefor
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US20020164571A1 (en) 2001-03-02 2002-11-07 Hammerman Marc R. Method of preserving metanephroi in vitro prior to transplantation
US20030153503A1 (en) 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
EP1968628A2 (en) * 2005-12-28 2008-09-17 Essential Skincare, LLC Transferrin and transferrin-based compositions for diabetes treatment
WO2007081654A2 (en) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
ES2705587T3 (es) 2006-06-26 2019-03-26 Akebia Therapeutics Inc Inhibidores de prolil hidroxilasa y métodos de uso
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
ITLU20070009A1 (it) * 2007-05-21 2008-11-22 Kedrion Spa Uso di transferrina per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni batteriche come coadiuvanti nella terapia antibiotica.
US8309583B2 (en) * 2007-11-01 2012-11-13 Rachel Codd Desferrioxamine conjugates, derivatives and analogues
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
CN103930103B (zh) 2011-10-12 2016-08-24 思佰益药业股份有限公司 移植器官的成活促进剂
ES2598627T5 (es) * 2011-11-11 2020-02-03 Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Apotransferrina para el tratamiento del ictus cerebral
US9763899B2 (en) * 2012-08-30 2017-09-19 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure during rejection episodes

Also Published As

Publication number Publication date
SG10201505207RA (en) 2016-02-26
ES2843783T3 (es) 2021-07-20
EP3300742A1 (en) 2018-04-04
AU2015203264B2 (en) 2019-08-22
PT3300742T (pt) 2021-01-25
KR20160007367A (ko) 2016-01-20
CN105288598A (zh) 2016-02-03
KR20190132966A (ko) 2019-11-29
TWI704926B (zh) 2020-09-21
KR102219557B1 (ko) 2021-02-24
ZA202203445B (en) 2022-09-28
TR201815058T4 (tr) 2018-11-21
US20160008437A1 (en) 2016-01-14
TW201622742A (zh) 2016-07-01
IL239655B (en) 2019-07-31
FI3795171T3 (fi) 2024-05-10
AU2015203264A1 (en) 2016-01-28
AU2021201445A1 (en) 2021-03-25
PT2977056T (pt) 2018-11-07
MX2015008310A (es) 2016-01-11
UY36173A (es) 2016-02-29
KR20210021339A (ko) 2021-02-25
EP2977056A3 (en) 2016-04-27
ES2693602T3 (es) 2018-12-12
AR101133A1 (es) 2016-11-23
ZA201504705B (en) 2022-09-28
NZ709399A (en) 2019-10-25
MX359029B (es) 2018-09-12
RU2015126920A (ru) 2017-01-10
CA2894239A1 (en) 2016-01-11
CA2894239C (en) 2023-05-09
HK1220895A1 (zh) 2017-05-19
CL2015001936A1 (es) 2015-12-28
EP3795171B1 (en) 2024-04-10
AU2019264588A1 (en) 2019-12-05
RU2686308C2 (ru) 2019-04-25
JP6517100B2 (ja) 2019-05-22
SG10201811078XA (en) 2019-01-30
NZ757595A (en) 2024-01-26
PL3300742T3 (pl) 2021-05-04
CA3191469A1 (en) 2016-01-11
CA3191475A1 (en) 2016-01-11
EP3795171A1 (en) 2021-03-24
KR102310000B1 (ko) 2021-10-07
PT3795171T (pt) 2024-05-08
MY184341A (en) 2021-04-01
RU2015126920A3 (pl) 2019-01-15
US9687530B2 (en) 2017-06-27
USRE49129E1 (en) 2022-07-12
EP2977056B1 (en) 2018-09-12
AU2021201445B2 (en) 2024-02-29
HUE053104T2 (hu) 2021-06-28
EP2977056A2 (en) 2016-01-27
BR102015015916A2 (pt) 2016-01-12
AU2019264588B2 (en) 2021-03-25
EP3300742B1 (en) 2020-11-04
JP2016020342A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
IL289475A (en) Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases
IL263484A (en) Pyrimidine-2-ylamino-h1-pyrazoles as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
IL264641B2 (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
PL2977056T3 (pl) Transferryna do zastosowania w leczeniu zaburzeń neurodegeneracyjnych związanych z czynnikiem indukowanym hipoksją (HIF)
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
IL250507B (en) Anti-ck8 antibodies for use in cancer treatment
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL252043B (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders